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Objectives: The main objective was to evaluate HBV infection and occult HBV infection (OBI)
cases in mentally ill patients based on serological and molecular proﬁles.
Material and methods: Serum samples of 333 long-stay mentally ill patients were tested for
the  prevalence of HBV markers by serological (ELISA) and molecular (PCR) assays. The PCR
products were sequenced to determine viral genotypes.
Results: It was observed a global prevalence of 12.9% (43/333) for HBV infection markers,
considering HBsAg and/or anti-HBc positivity. Fourteen samples tested positive for anti-HBs
alone. All samples positive (n = 57) for any HBV serological markers were tested for HBV-DNA
and  six were positive: HBsAg/anti-HBc (n = 1), anti-HBc/anti-HBs (n = 1), anti-HBs alone (n = 1),
and anti-HBc alone (n = 3). The rate of OBI was 9.2% (5/54) from samples that were anti-HBc
and/or anti-HBs positive. All sequenced samples were characterized as genotype A.
Conclusion: The high rate of HBV infections found in this study suggests the possibility of HBVtransmission due to risk factors displayed by some patients, and highlights the importance
of  vaccination of susceptible patients and the staff of that institution.
© 2015 Elsevier Editora Ltda. All rights reserved.ntroduction
epatitis B virus (HBV) infection is a global public health issue.
t is estimated that nearly two billion people worldwide have
erological evidence of past or present HBV infection, whereas
ore  than 240 million people, who are chronically infected,
re at high risk of death from liver complications such as
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413-8670/© 2015 Elsevier Editora Ltda. All rights reserved.cirrhosis and hepatocellular carcinoma (HCC). According to
the World Health Organization (WHO), more  than 780 thou-
sand people die every year as a consequence of acute or
chronic HBV infection.1,2rsitário, Sala 420 IPTSP/UFG, CEP: 74.605-050 Goiânia, Goiás, Brazil.
The natural course of HBV infection is determined by the
interactions between the host and the virus. Traditionally,
clearance of HBV surface antigen (HBsAg) followed by posi-
tivity for anti-HBs is considered as infection recovery. Chronic
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HBV infection is characterized by the persistence of HBsAg.
Therefore, HBsAg and anti-HBc total represent viral exposure
markers while anti-HBs is a surrogate for immunity against
HBV.3,4 Additionally, the use of molecular biology techniques
in the diagnosis of hepatitis B has allowed the identiﬁcation
of occult HBV infection (OBI) by detection of viral DNA that
may or may not be present in the serum of HBsAg-negative
individuals.5,6
The clinical importance of OBI is that it constitutes a pos-
sible source of viral transmission. It has also been associated
with the risk of disease reactivation during immunosuppres-
sion, and with progression to cirrhosis and/or HCC, since
viral activity may determine a continuous inﬂammatory
condition.7
OBI has been observed in the general population8 as
well as in distinct groups such as blood donors,9 trans-
plant recipients,10 and in HIV-infected individuals.11 Mentally
ill patients are also at risk for HBV infection, especially
because of their peculiar behavior.12,13 To our knowledge data
on HBV occurrence among these patients are limited, and
data on the literature have focused on prevalence of HBV
infection.14–19
This study shows data on the serological and molecular
proﬁles of HBV infection and OBI among long-stay mentally ill
patients in a care center from Brazil.
Material  and  methods
Study  population
A total of 333 blood samples from the same number of
mentally ill patients, including 121 males and 212 females,
were collected between July 2011 and January 2012. The
age of the study patients varied from ﬁve to 106 years
old: 78.7% of patients were in the range 11–60; 3.0% had
up to 10 years, and 18.3% were older than 60 years. Of
all patients 68.8% had more  than 10 years of stay time
in the institution and only 15 had evidence of vaccination
against HBV. These patients were institutionalized in a care
center in the state of Goias, Brazil, where they received
multidisciplinary care on the prevention, treatment, basic
hygiene, and nutrition due to their partial or total dependence
imposed by their disorders (physical, psychiatric, neurologi-
cal).
A written consent was obtained from the day care center
legal authority. The study was approved by the Ethics Com-
mittee of the Universidade Federal de Goiás (Protocol 182/11).
Detection  of  serological  markers
All serum samples were tested by ELISA for the presence
of anti-HBc (HEPANOSTIKA anti-HBc Uni-Form, bioMérieux,
France), anti-HBs (ANTI-SURASE B-96 (TMB) (General Bio-
logicals Corporation, Taiwan)), following the manufacturer’s
instructions. For HBsAg, two commercial EIA kits were used:
SURASE B-96 (General Biological Corporation, Taiwan) and
“HBsAg one” (DIA.PRO, Diagnostic Bioprobes SRl, Italy), both
with high sensitivity (100%) and speciﬁcity (99.5%), according
to the manufacturers. 1 5;1  9(6):643–647
HBV-DNA  detection
Serum samples that were positive for any of the HBV sero-
logical markers were submitted to DNA extraction using
phenol/chloroform20 and subjected to a semi-nested PCR
ampliﬁcation of the preS2/S genomic region. The test has sen-
sitivity to detect three DNA molecules per assay, as previous
described.21 The ﬁrst round of ampliﬁcation was performed
using sense primer PS1 (nt 2826–2845) and two antisense
primers S2 (nt 819–841) and S22 (nt 819–841). For second
round, sense primer PS1 and antisense primer SR (nt 685–704)
were used, generating a 1099 fragment base pairs. To avoid
cross-contamination, all procedures were performed in differ-
ent PCR cabinets, with UV light decontamination before and
after each step. Samples with distinct serological proﬁle were
tested separately, for each reaction and a negative control was
included. In order to conﬁrm the DNA-HBV positive samples,
all procedures were repeated. A second blood sample was also
obtained from each positive patient and re-tested.
Genotyping
The PCR products were sequenced as previously described,22
using the second-round primers and the ABI Prism Big
Dye Terminator 3.1 Cycle Sequencing Kit (Applied Biosys-
tems, Foster City, CA, USA). After puriﬁcation using QIAquick
PCR Puriﬁcation Kit (Qiagen, Freigburg, Germany), samples
were denatured and directly sequenced using an automated
sequencer (ABI 3130 Genetic Analyzer – Applied Biosystems,
Foster City, CA). The quality of each electropherogram was
evaluated using Phred software,23 and the sequences were
aligned by ClustalX software.24 The genotypes were identiﬁed
by phylogenetic reconstructions using reference sequences
from each HBV genotype obtained from GenBank, and the
tree was generated using the neighbor-joining algorithm
method.25 Genetic distances were determined by the Kimura-
2-parameters method26 using the software MEGA v.5.0.27
Results
Out of 333 samples, 57 were positive for at least one HBV sero-
logical marker, which included two samples HBsAg positive
alone, one HBsAg/anti-HBc, 26 anti-HBs/anti-HBc, 14 anti-HBc
alone, and 14 anti-HBs alone (Table 1). Considering the expo-
sure markers (HBsAg and/or anti-HBc) a global prevalence of
HBV infection was 12.9% (43/333).
Fifty-seven samples were screened for HBV DNA and
six of them were positive, with distinct serological proﬁles:
HBsAg/anti-HBc (n = 1), anti-HBc/anti-HBs (n = 1), anti-HBs
alone (n = 1) and anti-HBc alone (n = 3). Only samples positive
for anti-HBc and/or anti-HBs were considered OBI, and a rate
of 9.2% (5/54) was observed.
Nucleotide sequencing was performed successfully in all
DNA-HBV positive samples. Sequences with 511 bp of the
pre S2/S partial region (nt113–623) were considered for the
comparative analysis, which showed identities values vary-
ing from 98 to 99% in relation to the Brazilian isolate U55222,
and all of them were characterized as genotype A (GenBank
accession numbers KJ434163–KJ434168) (Fig. 1).
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Table 1 – HBV serological markers in 333 long-stay
mentally ill patients.
Markers No. % CI 95%
Infection markers
HBsAg 02 0.6 0.1–2.4
Anti-HBc 14 4.2 2.4–7.1
Anti-HBc/HBsAg 01 0.3 0.0–1.9
Anti-HBc/anti-HBs 26 7.8 5.2–11.3
Immunity marker
Anti-HBsa 14 4.2 2.4–7.1
Susceptibility
Negative for all markers 276 82.9 78.3–86.6
a From a total of 14 anti-HBs-positive patients, 10 had evidence of
previous vaccination against HBV.
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Discussion
The participants of the study were diagnosed as mentally
ill, associated or not to a physical disorder. Mentally inpa-
tients are at risk for HBV infection due to the special behavior
that they present.12,13 These individuals may share per-
sonal hygiene objects, such as tooth brushes and raisers.
They may also behave aggressively, which could potentially
result in minor abrasions or even lesions. Some are immune
compromised in addition to their mental problem.28 Further-
more, institutionalization may also increase the risk of HBV
transmission29 that appears to be mediated by both prolonged
contact between inpatients and behavior due to mental and
physical disabilities.
A rate of 12.9% for HBV infection was observed in this study
population by serological methods. These data corroborates
other studies16,18 although higher rates have been found in
previously published studies.14,28,30–32 Our data also revealed
a 9.2% (5/54) rate of OBI, reinforcing the notion that HBV infec-
tion is underestimated when HBV DNA is not tested in cases
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in whom the infection is assumed to be resolved (HBsAg neg-
ative, anti-HBc and/or anti-HBs positive cases).
The prevalence of OBI varies according to geographi-
cal regions as well as distinct populations. The OBI proﬁle
has been reported in different regions around of the world
with rates ranging from 0% to 50% in healthy patients and
blood donors.33–35 It has also been reported in 30–95% of
at-risk individuals such as chronic hepatitis C patients.36,37
Considering the OBI data in mentally ill inpatient popula-
tion, only one study was conducted with similar population
in Brazil, which detected HBV-DNA in 13.4% of HBsAg negative
samples.14
Among inpatients with OBI it is possible to observe differ-
ences in the serum markers proﬁle.5,38,39 Some studies have
shown that in general anti-HBc and/or anti-HBs markers are
present, however about 20% of patients are negative for both
markers.40 In this study, only positive patients for HBV mark-
ers were tested for HBV DNA, therefore the rate of OBI could
have been underestimated.
Although the anti-HBc/anti-HBs proﬁle is indicative of viral
clearance and immunity, when in association with viral DNA
positivity it is considered a case of persistent infection.41,42 On
the other hand, presence of anti-HBs does not always mean
protection against HBV infection, considering the circulation
of HBV mutants, for which the anti-HBs antibodies elicited by
the HBV vaccine may not be able to exert their neutralizing
activity. This fact could explain the occurrence of HBV infec-
tion in vaccinated individuals,43 as observed in one inpatient,
who  was positive for anti-HBs and HBV DNA (Fig. 1 – accession
number KJ434164).
Of the patients, only 4.2% were positive for anti-HBs alone
(immunity marker), and 82.9% were susceptible to infection.
The number of infected individuals (HBsAg and/or DNA posi-
tive) highlights the facilitation of the virus transmission in the
institution.
The HBV-DNA positive samples were characterized as
genotype A (Fig. 1). This genotype has a global distribution
and in Brazil it is the most prevalent, followed by genoypes
D and F.44–47 It has been suggested that acute infection with
HBV genotype A may increase the risk of progression to
chronic disease.48,49 Despite the risk factor associated with
HBV transmission that the patients may present, the phyloge-
netic analysis carried out with DNA sequences of six samples
showed that they were not identical, indicating no HBV trans-
mission among these patients.
Finally, studies on HBV prevalence that use methodolo-
gies that allow for the identiﬁcation of serologic proﬁles as
well as the presence of viral DNA are essential for identify-
ing infected people in order to minimize complications arising
from HBV infection and also to help decreasing viral dissem-
ination.
The presence of occult infection among long-stay mentally
ill patients is worrying considering not only the possibility
of progression to cirrhosis and carcinoma but also because
it may cause viral transmission, due to the living conditions
of the individuals. Therefore our data underscores the need
for periodic monitoring of inpatients for the possibility of
viral transmission and reinforce the importance of the adop-
tion of preventive vaccination against HBV of inpatients and
staff.
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